Introduction
============

It is estimated that in Australia in 2017, colorectal cancer (CRC) will be the second most diagnosed cancer and the third leading cause of cancer-related death.[@b1-ppa-12-1825] In 2015, Australia's National Bowel Cancer Screening Program (NBCSP) provided a free fecal immunochemical test (FIT) for men and women aged 50--74 years every 5 years, and the program is being gradually expanded to a biennial offer to those aged 50--74 years by 2020.[@b2-ppa-12-1825] The majority of countries with an organized population CRC screening program also provides the opportunity to utilize some form of fecal occult blood test (FOBT), either FIT or guiaic fecal occult blood test (gFOBT).[@b3-ppa-12-1825]--[@b5-ppa-12-1825] Despite evidence that screening with an FOBT can detect cancer and precancerous growth at an early stage,[@b6-ppa-12-1825]--[@b8-ppa-12-1825] thereby improving prognosis and reducing mortality,[@b9-ppa-12-1825]--[@b11-ppa-12-1825] participation in testing around the world is considered suboptimal with participation rates below 50% in many countries.[@b6-ppa-12-1825]--[@b8-ppa-12-1825] In Australia, the participation rate in the NBCSP of just 39.0% was achieved in the year 2014--2015[@b2-ppa-12-1825] although it must be recognized that one-quarter to one-third of people approached could already have been up to date with screening.[@b12-ppa-12-1825]

A key element of a successful population screening program is the achievement of high participation rates because early (curable) lesions that bleed can be found only in individuals who participate in the recommended screening at the recommended intervals. Participation rates are impacted by attitudinal and practical barriers including perceptions of test accuracy, preparation requirements, complexity of the testing process, the perceived likelihood or extent of pain,[@b13-ppa-12-1825],[@b14-ppa-12-1825] perceptions of the risk reduction achieved, the interval time between rescreening,[@b15-ppa-12-1825] and embarrassment.[@b16-ppa-12-1825] Fecal aversion, a term used to describe an attitude that fecal sampling is "unhygienic" and "distasteful," has also been identified as a contributor to poor fecal test participation.[@b17-ppa-12-1825],[@b18-ppa-12-1825] Taken together, a growing body of research suggests that screening program success is largely dependent on consumer evaluation of the requirements of a screening regimen, and fecal sampling, in particular, has to overcome "the perils of prudishness."[@b19-ppa-12-1825] Without optimal participation, screening cannot succeed as a public health population strategy, and it is apparent that test technology influences intended and actual participation.

Currently, new approaches to population screening for CRC that do not involve fecal sampling are at various stages of development. These include markers derived from biological fluids including saliva[@b20-ppa-12-1825],[@b21-ppa-12-1825] and blood.[@b22-ppa-12-1825]--[@b24-ppa-12-1825] The generally accepted attitude to these biomarkers is that they are likely to be preferred to current modalities because they would circumvent a number of barriers including fecal aversion.

Few studies to date have specifically examined, from a necessarily hypothetical perspective, the likelihood of greater population acceptance (and therefore potential for greater uptake) of alternative biomarkers as a substitute for, or complement to, the fecal test. Current evidence suggests that blood sampling may be preferred to stool,[@b25-ppa-12-1825],[@b26-ppa-12-1825] although this is not always the case,[@b27-ppa-12-1825],[@b28-ppa-12-1825] and a combination of, or choice between, stool and blood testing may be even preferred over either test individually.[@b25-ppa-12-1825] Other studies conducted in the context of preference for giving saliva, urine, or blood for medical testing have found that saliva was the preferred method over blood or urine when presented as a hypothetical possibility[@b29-ppa-12-1825] and after actual sample collection.[@b30-ppa-12-1825] It is clear that insufficient evidence exists concerning consumer preferences for screening modality, particularly when placed within plausible contexts where tests vary on critical dimensions likely to influence preferences such as test performance, method of sample collection, cost, and perceived convenience of sample collection location. In the light of this research gap, we utilized two approaches -- a ranking task and a discrete choice experiment (DCE) -- to examine the influence of these particular test attributes on consumer preferences for CRC screening modalities.

Ranking involves a respondent assigning a level of importance to each attribute that describes a test procedure separately. The measurement process requires an absolute judgment made in the context of a relative preference, whereas a DCE requires respondents to make trade-offs between stimuli according to underlying attributes with these presented in scenarios. DCEs are widely used in market research to determine which attributes of a product influence consumer preferences and to what extent consumers are prepared to "trade-off" one attribute against another. DCEs are also increasingly being utilized in health economics to determine patient preferences for health care options. A DCE approach to data collection and analysis provides the opportunity to identify critical attributes of a health action or service that determine preferences and their comparative importance to decision-making and to attach a monetary value to decisions.[@b31-ppa-12-1825]--[@b33-ppa-12-1825] A number of studies using the DCE method have compared test preferences for existing CRC screening (colonoscopy vs flexible sigmoidoscopy vs fecal test) have been conducted,[@b15-ppa-12-1825],[@b16-ppa-12-1825],[@b27-ppa-12-1825],[@b33-ppa-12-1825]--[@b35-ppa-12-1825] but none have examined hypothetical technologies or approaches.

We expanded the ranking and DCE exercises to include an investigation of demographic and psychological predictors of preferences for specific screening tests. Previous research has highlighted that aversion is negatively associated with acceptance of stool-based screening[@b17-ppa-12-1825],[@b26-ppa-12-1825] and that perception of convenience influences sample preference,[@b26-ppa-12-1825] and so we hypothesized that these two factors, aversion and convenience, influenced the acceptance of (hypothetical) blood and saliva collection for CRC screening. Thus, the aims of this study were as follows: to identify the relative importance of the separate attributes of sample type, perceived convenience of sample collection, test performance, and cost in the decision to utilize a specific form of CRC screening via a ranking and DCE exercise;to confirm that sample types rated as more aversive to provide would be less preferred and that perceived convenience of sample collection positively influences sample preference; andto explore demographic associations with affective response to sampling.

Materials and methods
=====================

Participant recruitment and study design
----------------------------------------

The Electoral Commission of South Australia provided a random sample of 3,000 names and addresses of men and women aged 50--74 years in selected urban and rural residential areas representing a range of socioeconomic status. No exclusion criteria were applied. Ethics approval was obtained from Flinders University Social and Behavioral Research Ethics Committee (5627 SBREC), and the study was conducted in Adelaide, Australia. All study invitees were informed about the aims of the study and its anonymous and voluntary nature, before providing their consent by the act of completing the survey.

Invitees were mailed an introductory letter 2 weeks prior to survey distribution, at which point there was an opportunity to opt out of the study. Invitees were advised that they would be asked to complete a web-based survey (SurveyMonkey, San Mateo, California, USA) but were able to request a paper version. They subsequently received a letter providing web access instructions or paper-based survey (if requested) as well as the option again to request a paper-based survey or to opt out. A complaints procedure form and a reply-paid envelope were also included. Four weeks after survey distribution, people who opted out were excluded from the study and those who had not completed the survey received a reminder letter and paper version of the survey. No further attempts were made to recruit non-respondents after this stage. Participants who completed a survey within 9 weeks of initial invitation constituted the survey sample.

Survey measures
---------------

The survey recorded responses to basic questions about demographic characteristics (age, gender, marital and employment status, educational level, country of birth, and cultural identification). The Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socio-Economic Disadvantage was utilized as an index of socioeconomic status. This is a broad measure of residential area disadvantage.[@b36-ppa-12-1825] A higher score indicates a relative lack of disadvantage in general, for example, few households with low incomes, few people with no qualifications, and few people in low skilled occupations.

Self-reported fecal test use was measured by one item, "I perform home stool tests for bowel cancer" (4-point Likert scale ranging from never \[1\] to always \[4\] with a not applicable choice provided). Responses were dichotomised to "never" (no FOBT use) and "any" (prior FOBT use), so that we could determine if responses varied among those who had experience with FOBT and those who did not. Emotions associated with the thoughts of stool, blood, and saliva testing, hereinafter termed "Affective Response to Sampling," were assessed via responses to scenarios describing the process of sample attainment for each sample collection method ([Table 1](#t1-ppa-12-1825){ref-type="table"}). The four statements described the process as unpleasant, unhygienic, embarrassing, and uncomfortable. Each scenario was scored on a 7-point Likert scale, where (1) represented strongly disagree and (7) strongly agree; thus, scores could range from 4 to 28, with higher scores indicating greater aversion. "Perceived Convenience of Sample Collection" was assessed on the basis of response to questions on test-taking requirements, captured on a 5-point Likert rating scale, where (1) indicated difficult to find time for and (5) easy to find time. Statements rated were as follows: attendance at an appointment at the doctor, attendance at a pathology center, and completing a test at home and sending a sample in the post for the blood, saliva, and stool tests, respectively.

Ranking test preference
-----------------------

Five survey questions were developed to determine respondent preferences for each test attribute: sample type (stool, blood, and saliva); sample collection location (home, pathology center, and doctor's office); test performance, defined as the capacity of the test to detect bowel cancer (70%, 80%, and 90% detection); cost of test (\$30, \$50, and \$80); and most preferred test attribute -- sample type, sample collection location, test performance, or test cost. Performance was included because previous research has shown test accuracy to be an important determinant of preference.[@b32-ppa-12-1825] We provided identical test accuracy options for the three sample types based on the plausible ability of the fecal test to detect bowel cancer specifically (rather than adenomas). Levi et al[@b37-ppa-12-1825] reported a 94% test sensitivity for detecting CRC, which is similar to our previous finding of 86% sensitivity for detecting CRC after a positive FIT.[@b38-ppa-12-1825] Cost test was included (notwithstanding that the cost of cancer screening in Australia is largely covered by the national health system) to ensure concordance with the DCE, which utilizes cost as a calculation of the health economics measure, willingness to pay (WTP). Respondents ranked their preferences from highest to lowest (ie, 1--3 for items 1--4 and 1--4 for item 5 with 1 indicating the top rank or the most preferred). Ties were allowed. Ranks were converted to scores, so that ranks 1, 2, 3, and 4 received corresponding scores of 4, 3, 2, and 1; missing values were allocated a numerical 0 score,[@b39-ppa-12-1825] so that means could be calculated. A mean was obtained for each sample type with a higher score indicating greater preference.

DCE
---

The DCE tested the relative influence of sample type (blood, feces, and saliva), test performance (70%, 80%, or 90% of cancers detected, as for the ranking exercise), and cost to the consumer for undertaking the test (\$30, \$50, or \$80 Australian) on choice. Cost was included as an attribute to estimate the WTP; WTP is a measure of the amount of money a person is willing to sacrifice to procure a good outcome or avoid something undesirable.

Specification of three levels for each of the three attributes resulted in 27 (=3[@b3-ppa-12-1825]) possible scenario permutations, and a total of 351 (=27 × 26/2) possible pairwise choices. Utilization of the fractional factorial design described by Street and Burgess[@b40-ppa-12-1825] reduced the number of choice scenarios into a manageable set of 27 choices for presentation. The resulting DCE design was blocked into three survey versions of nine pairs each. This design was 100% efficient for the estimation of main effects only. The random sample of invitees (n = 3,000) were sorted alphabetically by surname, and one of the three versions of the survey was systematically assigned in such a way that the first 1,000 invitees received the first version, the next 1,000 received the second version, and the remaining 1,000 received the final version.

Statistical analyses
--------------------

The unidimensionality and reliability (internal consistency) of multi-item scales constructed for this study were assessed by principal components analysis (PCA) and Cronbach's alpha co-efficient, respectively. Results and final items are summarized in [Table 2](#t2-ppa-12-1825){ref-type="table"}. Scales were developed for affective response to sampling and perceived convenience of sample collection. Items with a moderate to large correlation value (0.50--0.90)[@b41-ppa-12-1825],[@b42-ppa-12-1825] were aggregated to create a mean total score. The "Affective Response to Sampling" scale was unidimensional (ie, all four items loaded on one component with an eigenvalue exceeding 1 and explained 76%, 72%, and 89% of the variance for stool, blood, and saliva, respectively). Reliability for stool, blood, and saliva sampling was strong with alphas of 0.89, 0.85, and 0.96, respectively.

Four items comprising "Perceived Convenience of Sample Collection" were subjected to PCA, and two components with eigenvalues exceeding one were identified, explaining 60.2% and 25.8% of the variance, respectively, and with strong loadings. The two-factor solution, with two items loading on each factor, was supported by parallel analysis,[@b43-ppa-12-1825] and two items were termed "perceived convenience of external sample collection" and "perceived convenience of home sample collection". Each had good reliability with an alpha of 0.72 and 0.73, respectively.

For the ranking analysis, one-way repeated measures ANOVA was conducted to compare sample ranking scores. If multivariate test results indicated that there were significant differences at the *P* \< 0.05 level, post hoc analyses were conducted.

For the DCE analysis, data were analyzed within a random utility maximization framework using the conditional logit model.[@b44-ppa-12-1825] In this experiment, each respondent indicated their preferences between two screening scenarios differing on the three attributes (cost, test performance, and sample type) with nine choice questions in total. The empirical model to be estimated was specified as: $$U = \beta 1*\text{blood} + \beta 2*\text{saliva} + \beta 3*\text{efficacy}90 + \beta 4*\text{efficacy}80 + \beta 5*\text{cost} + \varepsilon,$$where *U* is the utility that individual receives from choosing alternative in each choice scenario, βi is a vector of coefficients reflecting the desirability of the attributes, and ε is a random term. Conditional on βi, it is assumed that ε is independent and identically distributed with Gumbel distribution.[@b44-ppa-12-1825] The cost attribute was treated as a continuous variable for the purposes of calculating WTP.[@b45-ppa-12-1825] We calculated WTP by dividing the estimated coefficients for sample type or test performance attributes by the estimated coefficient for the cost attribute. The 95% CIs were calculated using the bootstrap technique.[@b46-ppa-12-1825]

We performed univariate and multivariate multinomial regression analyses with sample preference (blood and saliva) as the separate dependent variable and using stool sampling as the referent. For the regression analyses, only those individuals who expressed a clear preference for a particular sample type (blood, stool, or saliva) were utilized, ie, those with equal preferences for a sample type were not included in the analysis (resultant n = 1,194). Predictive variables included categorical demographic measures (gender, age group, previous FOBT use, education, geographic location, partner status, employment, and SEIFA status, which was assessed by dichotomising the SEIFA score at the 50th percentile and comparing participants in decile *≤*5 (most disadvantaged) with those in decile ≥6 (least disadvantaged). The variables affective response to sampling, perceived convenience of external sample collection, and perceived convenience of home sample collection were included as continuous psychological measures. Results are presented as ORs. Finally, independent samples *t*-tests and one-way ANOVAs were used as appropriate to explore the relationship between demographic factors and affective response for each sample collection method.

Results
=======

Descriptive analyses
--------------------

Participant numbers and attrition rates are shown in [Figure 1](#f1-ppa-12-1825){ref-type="fig"}. The survey response rate was 42.7% (1,282/3,000). Chi-square analysis indicated that there was no statistically significant association between gender and participation status (*P* = 0.30). There was a significant association for age (*P* \> 0.001); further examination of each age band's observed vs expected frequencies indicated that less people aged 50--54 years and more people aged 65--69 years participated in the survey. [Table 3](#t3-ppa-12-1825){ref-type="table"} provides participant demographic details for each survey version group. There were no statistically significant differences across groups for any of these characteristics. Taking the group as a whole, participation in the paper version of the survey (747/1,282, 58.3%) was higher than the web-based version (535/1,282, 41.7%). The majority of participants were living in a less disadvantaged area (742/1,282, 57.9%). Less than half the participants were in full- or part-time employment (533/1,248, 42.7%), which may reflect the fact that 43.4% (557/1,282) of participants were aged 65 years and older. Over half of the survey respondents (750/1,258, 59.6%) indicated that they had previous experience with FOBT. The majority of respondents were born in Australia.

Relative importance of screening attributes: ranking results
------------------------------------------------------------

Results of ranking attributes (means, SDs, and effect sizes) are shown in [Table 4](#t4-ppa-12-1825){ref-type="table"}. One-way repeated measures ANOVA was used to compare scores for each attribute item; all attributes showed statistically significant differences (*P* \< 0.001) with medium to large effect sizes. Post hoc analyses indicated that for sample type saliva and blood were equally preferred, and stool was the least preferred. For convenience of sample collection location, collection at both home and the doctor were equally preferred and collection at a pathology center was less preferred. Test performance of 90% was the most preferred, followed by 80% and lastly by 70%. A test cost of \$30 was the most preferred, followed by \$50 and lastly a cost of \$80 per test. Mean scores for perceived importance of test attribute (sample type, convenience, performance, and cost) indicated that test performance was regarded as the most important attribute of a screening test, followed equally by convenience and sample type and lastly test cost.

Relative importance of screening attributes: DCE results
--------------------------------------------------------

Ninety-six percent of respondents (1,231/1,282) answered all nine pairs of choice scenarios and were included in the conditional logit regression analysis, results from which are presented in [Table 5](#t5-ppa-12-1825){ref-type="table"}. All attributes were statistically significant. The sign and magnitude of the coefficients attached to test performance and the cost attributes indicated that respondents would prefer screening tests with higher performance and lower cost. Analysis confirmed that the results were largely uninfluenced by demographic characteristics, mode of survey administration, previous test experience, and attitude toward the CRC screening test.

The WTP estimates for the full sample are also reported in [Table 5](#t5-ppa-12-1825){ref-type="table"}. Participants were willing to pay \$13 on average for a blood sample test and \$8 for saliva; in contrast, the negative coefficient for the stool sample type suggests that respondents required a payment of \$21 to participate in a stool test.

Test performance trade-offs were consistent with the hypothesis; on average, respondents were willing to pay \$87 and \$1 for a 90% and 80% cancer detection rate, respectively. In the context of better performance being available, the negative coefficient on the 70% detection rate suggests that respondents required a payment of \$89 to have this test.

The relationship of demographic and psychological characteristics to relative preference for blood and saliva sampling compared to FIT
--------------------------------------------------------------------------------------------------------------------------------------

To address Aim 2 and test our hypothesis that affective responses to a sample and convenience of sample collection are significant psychological predictors of sample preference, we conducted univariate and multinomial regression analyses with FIT sampling, "usual care" within Australia, as the referent. Results, presented as ORs, are summarized in [Table 6](#t6-ppa-12-1825){ref-type="table"}. Fully adjusted multivariate models showed that higher negative affective response to FIT and saliva sample collection, and lower perceived convenience of home collection, resulted in a preference for blood testing. Similarly, negative affective response to FIT and blood sample collection and lower perceived convenience of home sample collection resulted in a preference for saliva collection.

The relationship of demographic characteristics to affective response to sampling
---------------------------------------------------------------------------------

To address Aim 3 and explore demographic associations with affective response to sampling, participants were asked to indicate their level of negative affective response to each sampling mode based on sample collection scenarios ([Table 1](#t1-ppa-12-1825){ref-type="table"}). Bivariate analyses indicated significant associations for some but not all demographic variables. For stool testing, those who had not previously screened with FIT were more averse to stool testing (mean = 14.3, SD = 5.8) than those who had previously screened (mean = 11.5, SD = 5.3, *P* \< 0.001). For blood collection, men were more averse (mean = 9.5, SD = 4.9) than women (mean = 8.9, SD = 4.6, *P* \< 0.05), as were people who lived in a less disadvantaged area (mean = 9.6, SD = 4.8 vs 8.7, SD = 4.7, *P* \< 0.01). For saliva collection, unemployed participants were more averse compared to those who were employed (mean = 9.0, SD = 5.3 vs mean = 8.1, SD = 4.5, *P* \< 0.01), and participants aged between 70 and 74 years (mean = 9.4, SD = 5.6) were significantly more averse than younger participants aged 50--59 years (mean = 8.1, SD = 4.6, *P* \< 0.05). All significant results were very small effects, with the largest (0.6) reported for the relationship between no prior FOBT screening and higher negative affective response to stool testing.

Discussion
==========

Given the suboptimal participation rates in current population-based CRC screening tests in Australia (ie, stool-based FOBT) and emerging evidence of the utility of potential alternative CRC biomarkers such as blood and saliva, the purpose of this study was to determine whether population preferences exist for CRC screening tests that vary on various test attributes. In particular, we tested the influence of aversion to sample type and perception of convenience, expressed as finding time to provide a sample. In addition, we measured how performance, cost, and sample impacted discrete choices.

The results from the DCE demonstrate that all three attributes, cost, test performance, and sample type, significantly impacted on respondents' preferences. Results from the WTP analysis further suggest that test performance is a more influential attribute than sample type. These results were consistent with the preference ranking exercise, which indicated that overall the most highly ranked attribute, whatever the sampling method, was test performance. These results are consistent with other studies[@b13-ppa-12-1825],[@b47-ppa-12-1825] even though previous work has compared more invasive tests (eg, FOBT and/or flexible sigmoidoscopy or colonoscopy). At the time this study was conducted, few data were available relating to the effectiveness of blood and saliva testing to detect CRC, and so we presented hypothetical performance levels for blood and saliva based on plausible levels of FIT sensitivity. Since that time, additional support for the FIT performance levels chosen has been provided by an analysis conducted by Australia's NBCSP, which indicated 83% FIT sensitivity for CRC over the years 2006--2008.[@b6-ppa-12-1825] Recent research[@b48-ppa-12-1825] examining the utility of blood and saliva to detect CRC has shown comparable CRC sensitivity levels for fecal and blood tests (64% and 62%, respectively), and Sazanov et al[@b49-ppa-12-1825] in 2017 reported that microRNA-21 expression in saliva had a sensitivity of 97% for detection of CRC. These results suggest that the hypothetical test performance levels for all three screening modalities were within real-world detection possibilities.

To the best of our knowledge, this is one of the few studies of this kind to incorporate sample type as an attribute for consideration in a test of choice of CRC screening approaches. Consistent with our own past research,[@b17-ppa-12-1825],[@b50-ppa-12-1825] fecal aversion was shown to impact FIT acceptability, but our findings also highlighted the importance of attention to other test attributes. When the impact of attributes is considered together, results from the DCE and ranking exercise confirmed highest acceptability for blood sampling followed by saliva although the difference between these two was reduced to non-significance in the ranking task. This finding is consistent with our previous research,[@b28-ppa-12-1825] where we showed that when a group of community volunteers and South Australian electoral roll registrants were offered a choice of blood or stool test, the majority preferred a blood test (79.6% vs 20.4%, respectively, from 1,561 respondents). Although there was evidence that, consistent with past research,[@b26-ppa-12-1825] previous use of a FIT resulted in lower fecal aversion, in multivariate analysis, previous FIT screening was not a significant predictor of preference for stool sampling.

An explanation for the preference for blood testing likely rests with a number of characteristics of this approach. Although blood sampling could be described as the most physically invasive of the three procedures under consideration, it is both familiar and trusted because it is utilized for a variety of medical diagnostic purposes. It requires little from the person in terms of active participation, particularly where fasting is not required. Nonetheless, not all population groups were equally accepting; in our study, men were more averse to blood collection than women, albeit with a small effect size. This observation confirms previous findings by us,[@b28-ppa-12-1825] where univariate analysis of data from n = 1,561 indicated that men were more likely to prefer provision of a stool sample over a hypothetical blood test. It is interesting to note that, notwithstanding these findings, male participation in the NBCSP has been consistently lower than female participation,[@b51-ppa-12-1825]--[@b53-ppa-12-1825] and our results point to the possibility that male-specific barriers to screening need to be addressed in the context of stool-based screening as much as for blood.[@b54-ppa-12-1825]--[@b57-ppa-12-1825]

A limitation of the results is that they are based on the largely hypothetical nature of the alternate screening technologies described. Although the respondents were given a detailed description of the proposed test procedure, preferences were decided based on individuals constructing a schema for how testing "might" work. For blood testing, this was not difficult, given the ubiquitous nature of this procedure currently. This contrasts with saliva, which is much less collected as a biological specimen, although it is becoming increasingly utilized for medical tests, particularly those involving DNA sampling.[@b58-ppa-12-1825]

Notwithstanding this limitation, the results suggest that, in the current environment, people exhibit higher aversion to fecal sampling, even given previous FIT screening. This suggests that CRC screening participation rates might be improved if sampling moved away from feces. Extensive work is currently being completed around the world to validate blood sampling for CRC screening.[@b59-ppa-12-1825],[@b60-ppa-12-1825] In addition, collection of saliva to identify genetic lifetime risk for CRC is also showing potential for use as a screen for surveillance program enrolment eligibility.[@b61-ppa-12-1825],[@b62-ppa-12-1825] Future research should evaluate whether an adjusted choice of test performance levels for blood and saliva testing, based on discrete results, alters patient preference, Alternatively, the use of blood testing as a second-line adjunct for FIT non-participants has been shown to increase overall screening rates.[@b63-ppa-12-1825]

Conclusion
==========

The findings of this research confirm our expectation that affective response (aversion) to sample type and perceived inconvenience of sample collection (in particular home sample collection) are significant drivers of screening preference. Test performance was the most important attribute of a screening test, regardless of sample preference. Further research should address the potential for the development of a test, or combination of tests, that combine the attributes of high performance, low aversion, and convenience of use to increase screening participation rates.
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###### 

Affective response to sampling: stool, blood, and saliva collection scenarios

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stool sample                                                                                                                                                                                                                                               Blood sample                                                                                                                                                              Saliva sample
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  1\. Obtain a home stool test kit (from your doctor, the chemist, or other provider). It contains collection paper, two sample containers with a collection stick attached to the inside of the cap, manufacturer's instructions, and a return envelope.\   1\. Visit a doctor or a local pathology collection center.\                                                                                                               1\. Visit a doctor or a local pathology collection center.\
  2. For the first sample, pass the bowel motion (stool) on to the collection paper placed inside the toilet bowel.\                                                                                                                                         2. A health professional uses a needle to collect a blood sample from your arm at the doctor's surgery[a](#tfn2-ppa-12-1825){ref-type="table-fn"} or pathology center.\   2. A health professional provides you with a small container to collect a saliva sample.\
  3. The collection stick is used to collect a small sample of stool (equivalent to a few grains of rice) and then to place back into the sample container.\                                                                                                 3. The tube of blood is transported to a local testing laboratory.\                                                                                                       3. You are required to deposit about a teaspoon of saliva from\
  4. The process is repeated on another bowel motion.\                                                                                                                                                                                                       4. Results are sent to your doctor as soon as they are available.                                                                                                         your mouth into the container.\
  5. Both completed samples are placed into the return envelope supplied and posted to the testing laboratory.\                                                                                                                                                                                                                                                                                                                        4. The container of saliva is transported to a local testing laboratory.\
  6. Results are posted to you as soon as they are available.                                                                                                                                                                                                                                                                                                                                                                          5. Results are sent to your doctor as soon as they are available.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Given the following scenarios, on a scale of 1--7 where 1 is strongly disagree and 7 is strongly agree, providing a sample would be 1) unpleasant, 2) unhygienic, 3) embarrassing, and 4) uncomfortable.

Equivalent to "doctor's office."

###### 

List of multiscale and single items and descriptive statistics

  Scale name                                                                            Item description                                                                                      Mean (SD) score   Cronbach's alpha
  ------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------- ------------------
  Affective response to sampling -- stool (n = 1,217, maximum score = 28)               Collecting a stool sample would be 1) unpleasant; 2) unhygienic; 3) embarrassing; 4) uncomfortable    12.61 (5.68)      0.892
  Affective response to sampling -- blood (n = 1,232, maximum score = 28)               Collecting a blood sample would be 1) unpleasant; 2) unhygienic; 3) embarrassing; 4) uncomfortable    9.14 (4.75)       0.851
  Affective response to sampling -- saliva (n = 1,236, maximum score = 28)              Collecting a saliva sample would be 1) unpleasant; 2) unhygienic; 3) embarrassing; 4) uncomfortable   8.59 (4.97)       0.957
  Perceived convenience of external sample collection (n = 1,262, maximum score = 10)   Finding the time to attend an appointment at the 1) doctor; 2) pathology center                       7.13 (2.29)       0.833
  Perceived convenience of home sample collection (n = 1,262, maximum score = 10)       Finding time to 1) complete a test at home; 2) send a sample in the post                              8.49 (1.76)       0.840

###### 

Demographic characteristics of survey participants by DCE version allocated

  -----------------------------------------------------------------------------------------------------------------------------------------------
  Demographic characteristics                        Version 1,\   Version 2,\   Version 3,\   Total N
                                                     n (%)         n (%)         n (%)         
  -------------------------------------------------- ------------- ------------- ------------- --------------------------------------------------
  Sample                                             438           420           424           1,282[a](#tfn3-ppa-12-1825){ref-type="table-fn"}

  Survey type                                                                                  

   Web                                               176 (40.2)    170 (40.5)    189 (44.6)    535 (41.7)

   Paper                                             262           250           235           747

  Gender                                                                                       

   Male                                              207 (47.3)    197 (46.9)    207 (48.8)    611 (47.7)

   Female                                            231           223           217           671

  Age, years (n = 1,282)                                                                       

   50--54                                            72 (16.4)     72 (17.1)     73 (17.2)     217 (16.9)

   55--59                                            88 (20.1)     71 (16.9)     82 (19.3)     241 (18.8)

   60--64                                            89 (20.3)     85 (20.2)     93 (21.9)     267 (20.8)

   65--69                                            96 (21.9)     95 (22.6)     98 (23.1)     289 (22.6)

   70--74                                            93 (22.2)     97 (23.1)     78 (18.4)     268 (20.9)

  Location                                                                                     

   Urban                                             336 (76.7)    319 (76.0)    325 (76.7)    980 (76.4)

   Rural                                             102           101           99            302

  Marital status                                                                               

   Yes                                               339 (77.4)    327 (77.9)    305 (71.9)    971 (75.7)

   No                                                86            79            105           270

  Employment status                                                                            

   In workforce                                      176 (40.2)    173 (41.2)    184 (43.4)    533 (41.6)

   Not in workforce                                  253           235           227           715

  Education level                                                                              

   \<Year 12                                         190 (43.4)    176 (41.9)    179 (42.2)    545 (42.5)

   ≥Year 12                                          236           231           230           697

  SEIFA[b](#tfn4-ppa-12-1825){ref-type="table-fn"}                                             

   *≤*5                                              185 (42.2)    175 (41.7)    180 (42.5)    540 (42.1)

   ≥6                                                253           245           244           742

  Born in Australia                                                                            

   Yes                                               322 (73.5)    316 (75.2)    308 (72.6)    946 (73.8)

   No                                                102           91            103           296

  Prior FOBT experience                                                                        

   Yes                                               248 (56.6)    258 (61.4)    244 (57.5)    750 (58.5)

   No                                                185           155           168           508
  -----------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Not all questions were completed by all participants; the numbers indicated above are not based on the total number of respondents.

SEIFA: decile *≤*5, most disadvantaged; decile ≥6, least disadvantaged.

**Abbreviations:** DCE, discrete choice experiment; FOBT, fecal occult blood test; SEIFA, Socio-Economic Indexes for Areas.

###### 

Preference scores for screening test attributes, transformed from rankings

  Attribute (score range)             Item          Mean score (SD)   *df*       *F*                                                   η[@b2-ppa-12-1825]
  ----------------------------------- ------------- ----------------- ---------- ----------------------------------------------------- --------------------
  Sample type (0--3)                  Saliva        2.18 (0.87)       2, 1,280   152.88[a](#tfn6-ppa-12-1825){ref-type="table-fn"}     0.193
  Blood                               2.12 (0.81)                                                                                      
  Stool                               1.56 (0.87)                                                                                      
  Sample collection location (0--3)   Home          2.08 (0.97)       2, 1,280   68.71[a](#tfn6-ppa-12-1825){ref-type="table-fn"}      0.097
  Doctor's surgery                    2.06 (0.80)                                                                                      
  Pathology center                    1.70 (0.84)                                                                                      
  Test performance (0--3)             90%           2.84 (0.60)       2, 1,280   3,951.35[a](#tfn6-ppa-12-1825){ref-type="table-fn"}   0.861
  80%                                 1.94 (0.45)                                                                                      
  70%                                 1.03 (0.40)                                                                                      
  Test cost (0--3)                    \$30          2.52 (0.87)       2, 1,280   744.97[a](#tfn6-ppa-12-1825){ref-type="table-fn"}     0.538
  \$50                                2.04 (0.58)                                                                                      
  \$80                                1.23 (0.71)                                                                                      
  Test attributes (0--4)              Performance   3.55 (0.92)       3, 1,279   905.49[a](#tfn6-ppa-12-1825){ref-type="table-fn"}     0.680
  Convenience                         2.37 (0.94)                                                                                      
  Sample type                         2.34 (1.10)                                                                                      
  Cost                                1.71 (1.04)                                                                                      

**Note:**

*P* \< 0.001.

###### 

Conditional logit estimates for individual's preferences for colorectal cancer screening test and marginal rates of substitution with respect to cost (N = 1,231)

  Attributes       Levels   Coefficient   Cluster robust SE                                  WTP (AUD)   95% CI (lower)   95% CI (upper)
  ---------------- -------- ------------- -------------------------------------------------- ----------- ---------------- ----------------
  Sample type      Stool    −0.353        0.023[a](#tfn8-ppa-12-1825){ref-type="table-fn"}   −20.950     −25.188          −17.163
                   Saliva   0.134         0.022[a](#tfn8-ppa-12-1825){ref-type="table-fn"}   7.965       5.399            10.634
                   Blood    0.219         0.023[a](#tfn8-ppa-12-1825){ref-type="table-fn"}   12.985      9.942            16.419
  Test             70%      −1.495        0.024[a](#tfn8-ppa-12-1825){ref-type="table-fn"}   −88.768     −98.414          −80.636
  performance      80%      0.023         0.011[b](#tfn9-ppa-12-1825){ref-type="table-fn"}   1.365       0.126            2.653
                   90%      1.472         0.038[a](#tfn8-ppa-12-1825){ref-type="table-fn"}   87.403      79.292           97.028
  Cost                      −0.017        0.001[a](#tfn8-ppa-12-1825){ref-type="table-fn"}   --          --               --
  Log likelihood            −4,312.525                                                                                    
  Observations              11,079                                                                                        

**Notes:** Conditional logit estimates reported in the table. Cost attribute was included as a continuous variable; all other attributes were effect coded. CIs estimated using bootstrap method (with 10,000 replications).

*P* \< 0.01;

*P* \< 0.05.

**Abbreviations:** AUD, Australian dollar; SE, standard error; WTP, willingness to pay.

###### 

Associations between demographic and psychological characteristics with preference for blood and saliva testing compared to FOBT

  Demographic characteristics                           Sample   Preference for blood (univariate)   Preference for blood (multivariate)                Preference for saliva (univariate)   Preference for saliva (multivariate)                                                                                                                                                                                                                     
  ----------------------------------------------------- -------- ----------------------------------- -------------------------------------------------- ------------------------------------ -------------------------------------- -------------------------------------------------- ------------ -------- -------------------------------------------------- ------------ -------- -------------------------------------------------- ------------ --------
  50--59 years                                          423      35.4                                0.70                                               0.45--1.10                           −0.351                                 0.73                                               0.43--1.25   −0.316   1.46                                               0.94--2.26   0.376    --                                                 --           --
  60--69 years                                          524      43.9                                0.59[c](#tfn14-ppa-12-1825){ref-type="table-fn"}   0.39--0.90                           −0.522                                 0.63                                               0.39--1.02   −0.465   0.91                                               0.60--1.39   −0.091   --                                                 --           --
  70+ years                                             247      20.7                                1                                                  --                                   --                                     --                                                 --           --       1                                                  --           --       --                                                 --           --
  Female                                                630      52.8                                1                                                  --                                   --                                     --                                                 --           --       1                                                  --           --       --                                                 --           --
  Male                                                  564      47.2                                0.80                                               0.58--1.09                           −0.230                                 --                                                 --           --       0.90                                               0.67--1.22   −0.106   --                                                 --           --
  No previous FOBT screening                            472      40.3                                2.18[a](#tfn12-ppa-12-1825){ref-type="table-fn"}   1.55--3.05                           0.777                                  1.35                                               0.92--1.99   0.300    1.64[b](#tfn13-ppa-12-1825){ref-type="table-fn"}   1.18--2.27   0.492    1.17                                               0.81--1.69   0.154
  Previous FOBT screening                               700      59.7                                1                                                  --                                   --                                     --                                                 --           --       1                                                  --           --       1                                                  --           --
  \<Year 12 education                                   514      44.0                                1.24                                               0.90--1.70                           0.212                                  --                                                 --           --       0.64[b](#tfn13-ppa-12-1825){ref-type="table-fn"}   0.47--0.87   −0.455   0.732                                              0.52--1.04   −0.312
  ≥Year 12 education                                    653      56.0                                1                                                  --                                   --                                     --                                                 --           --       1                                                  --           --       --                                                 --           --
  Urban living                                          911      76.3                                0.80                                               0.56--1.15                           −0.222                                 --                                                 --           --       1.26                                               0.88--1.81   0.230    --                                                 --           --
  Rural living                                          283      23.7                                1                                                  --                                   --                                     --                                                 --           --       1                                                  --           --       --                                                 --           --
  Partner                                               915      78.6                                1                                                  --                                   --                                     --                                                 --           --       1                                                  --           --       --                                                 --           --
  No partner                                            249      21.4                                0.55                                               0.61--1.30                           −0.117                                 --                                                 --           --       0.81                                               0.56--1.16   −0.215   --                                                 --           --
  Employed                                              508      43.4                                1                                                  --                                   --                                     --                                                 --           --       1                                                  --           --       --                                                 --           --
  Not employed                                          662      56.6                                1.36                                               0.98--1.89                           0.308                                  --                                                 --           --       0.80                                               0.59--1.09   −0.219   --                                                 --           --
  SEIFA most disadvantaged                              495      41.5                                1.09                                               0.79--1.49                           0.083                                  --                                                 --           --       0.72[c](#tfn14-ppa-12-1825){ref-type="table-fn"}   0.53--0.98   −0.332   1.09                                               0.75--1.58   0.087
  SEIFA least disadvantaged                             699      58.5                                1                                                  --                                   --                                     --                                                 --           --       1                                                  --           --       --                                                 --           --
  Affective response to FIT collection                  1,139                                        1.17[a](#tfn12-ppa-12-1825){ref-type="table-fn"}   1.13--1.21                           0.153                                  1.17[a](#tfn12-ppa-12-1825){ref-type="table-fn"}   1.12--1.22   0.155    1.13[a](#tfn12-ppa-12-1825){ref-type="table-fn"}   1.09--1.16   0.117    1.15[a](#tfn12-ppa-12-1825){ref-type="table-fn"}   1.10--1.20   0.139
  Affective response to blood collection                1,154                                        1.00                                               0.96--1.03                           −0.003                                 --                                                 --           --       1.05[b](#tfn13-ppa-12-1825){ref-type="table-fn"}   1.02--1.09   0.049    1.06[b](#tfn13-ppa-12-1825){ref-type="table-fn"}   1.01--1.12   0.059
  Affective response to saliva collection               1,157                                        1.07[a](#tfn12-ppa-12-1825){ref-type="table-fn"}   1.01--1.12                           0.071                                  1.06[c](#tfn14-ppa-12-1825){ref-type="table-fn"}   1.01--1.12   0.062    0.99                                               0.95--1.02   −0.014   --                                                 --           --
  Perceived convenience of home sample collection       1,180                                        0.69[a](#tfn12-ppa-12-1825){ref-type="table-fn"}   0.61--0.77                           −0.371                                 0.72[a](#tfn12-ppa-12-1825){ref-type="table-fn"}   0.62--0.83   −0.330   0.76[a](#tfn12-ppa-12-1825){ref-type="table-fn"}   0.68--0.85   −0.278   0.81[c](#tfn14-ppa-12-1825){ref-type="table-fn"}   0.71--0.94   −0.206
  Perceived convenience of external sample collection   1,178                                        1.00                                               0.94--1.08                           0.004                                  --                                                 --           --       0.91[b](#tfn13-ppa-12-1825){ref-type="table-fn"}   0.85--0.97   −0.095   1.03                                               0.94--1.12   0.027

**Notes:** Analysis -- multinomial logistic regression.

*P* \< 0.001.

*P* \< 0.01.

*P ≤* 0.05.

**Abbreviations:** FIT, fecal immunochemical test; FOBT, fecal occult blood test; SEIFA, Socio-Economic Indexes for Areas.
